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Abstract
1. We have previously demonstrated that a small molecule inhibitor of bacterial β-
glucuronidase (Inh-1; [1-((6,8-dimethyl-2-oxo-1,2-dihydroquinolin-3-yl)-3-(4-
ethoxyphenyl)-1-(2-hydroxyethyl)thiourea]) protected mice against diclofenac (DCF)-
induced enteropathy. Here we report that Inh-1 was equally protective against small
intestinal injury induced by other carboxylic acid-containing non-steroidal anti-
inflammatory drugs (NSAIDs), indomethacin (10 mg/kg, ip) and ketoprofen (100 mg/kg,
ip).
2. Inh-1 provided complete protection if given prior to DCF (60 mg/kg, ip), and partial
protection if administered 3-h post-DCF, suggesting that the temporal window of
mucosal protection can be extended for drugs undergoing extensive enterohepatic
circulation.
3. Pharmacokinetic analysis of Inh-1 revealed an absolute bioavailability (F) of 21% and a
short t1/2 of <1 h. This low F was shown to be due to hepatic first-pass metabolism, as
confirmed with the pan-CYP inhibitor, 1-aminobenzotriazole.
4. Using the fluorescent probe 5 (and 6)-carboxy-2′,7′-dichlorofluorescein, we demonstrated
that Inh-1 did not interfere with hepatobiliary export of glucuronides in gall bladder-
cannulated mice.
5. These data are compatible with the hypothesis that pharmacological inhibition of
bacterial β-glucuronidase-mediated cleavage of NSAID glucuronides in the small
intestinal lumen can protect against NSAID-induced enteropathy caused by locally high
concentrations of NSAID aglycones.
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Non-steroidal anti-inflammatory drugs (NSAIDs), despite being generally safe drugs, have
the potential to produce widespread gastrointestinal adverse drug reactions. These include
not only gastroduodenal injury but also mucosal erosions and ulceration in the small
intestine (Scarpignato & Hunt, 2010; Wallace, 2012). Although often clinically silent
initially, when taken long-term, the complications associated with NSAID-induced
enteropathy (bleeding, protein loss, strictures, and, rarely, perforations) may become serious
(Bjarnason, 2013). To date, there are no clinically approved effective therapies available to
prevent or treat NSAID-induced enteropathy.
One reason for the lack of effective therapies is our incomplete understanding of the
mechanisms underlying NSAID enteropathy. It has become clear that the pathogenesis is a
multi-step sequence of events involving multiple mechanisms (Boelsterli et al., 2013). In the
mucosal epithelia (enterocytes), NSAIDs or their reactive metabolites can cause
endoplasmic reticulum stress and mitochondrial stress, which can lead to epithelial cell
injury and cell death. This is followed by an increase in the epithelial permeability, bacterial
migration into deeper layers of the mucosa and activation of an inflammatory cascade
mediated by toll-like receptors, and amplification of the injury by an inflammatory response,
resulting in deep ulceration of the mucosa. These events can be modulated by other factors
(including prostaglandin synthase inhibition by the NSAIDs).
However, at the top of these cascades of events, a crucial determinant is the hepatobiliary
export of NSAID glucuronides, which is common for many NSAIDs. Specifically,
carboxylic acid-containing NSAIDs can form acyl glucuronides, and ring hydroxylation can
lead to phenol glucuronides, or a combination of the two glucuronidation steps. Both acyl
glucuronides and phenol glucuronides of diclofenac (DCF) have recently been identified in
mice following a single administration of the drug (Sarda et al., 2012). These glucuronides
are delivered to the small intestinal lumen, where they are cleaved by bacterial β-
glucuronidase, releasing the aglycones. The enterocytes thus become exposed to relatively
high concentrations of the free parent and oxidative metabolites, where they are believed to
cause mitochondrial and ER stress.
We have previously demonstrated in a mouse model of DCF-induced enteropathy (Ramirez-
Alcantara et al., 2009) that inhibition of β-glucuronidase with Inhibitor-1 (Inh-1), a small
molecule inhibitor of the bacteria-specific forms of β-glucuronidase (Wallace et al., 2010),
can greatly reduce the extent of DCF-induced enteropathy (LoGuidice et al., 2012).
However, it is not known whether this protective effect is selective for DCF or more
generally applicable to other cholephilic NSAIDs. Furthermore, the mode of action and the
disposition of these β-glucuronidase inhibitors are incompletely characterized. Therefore,
this follow-up study was aimed at exploring whether the same mechanism of protection
could be expanded to other carboxylic acid-containing NSAIDs and at further characterizing




Indomethacin, ketoprofen, diclofenac, 5 (and 6)-carboxy-2′,7′-dichlorofluorescein (CDF), 5
(and 6)-carboxy-2′,7′-dichlorofluorescein diacetate (CDFDA), and cyclosporin A were
obtained from Sigma-Aldrich (St. Louis, MO). Inhibitor-1 [1-((6,8-dimethyl-2-oxo-1,2-
dihydroquinolin-3-yl)methyl)-3-(4-ethoxyphenyl)-1-(2-hydroxyethyl)thiourea] was obtained
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from Asinex, Inc. (Winston-Salem, NC); its structure was confirmed by MS, and the purity
was 99%. Solutol HS-15 was from BASF (Ludwigshafen, Germany).
Animals and drug treatment
Male C57BL/6J mice were obtained from The Jackson Laboratory (Bar Harbor, ME). The
mice were acclimatized for 1 week and were 10 to 12 weeks of age at the start of the
experiments. The animals were kept on a 14/10-h light/dark cycle. They received mouse
chow (Teklad Global Rodent Diet; Harlan Laboratories, Boston, MA) and water ad libitum.
All studies were approved by the Institutional Animal Care and Use Committee of the
University of Connecticut. Indomethacin, ketoprofen and diclofenac were dissolved in 10%
(in phosphate-buffered saline) Solutol HS-15 solution and administered intraperitoneally in
a volume of 10 μl/g body weight. For pretreatment studies, Inh-1 or vehicle (0.5% aqueous
methyl cellulose) was administered by oral gavage b.i.d. (10 μg per mouse), starting 1 day
before indomethacin or ketoprofen administration and with the last dose given 1 h before
indomethacin or ketoprofen; for post-treatment studies, Inh-1 or vehicle was administered as
a single dose by oral gavage (10 μg per mouse) 3 h after DCF. The dosage regimen for Inh-1
was adopted from a previously published study (Wallace et al., 2010). For the
toxicopathology studies, 5–11 mice per treatment group were used, and for the kinetic study,
nine mice per treatment group (three mice for identical time points). The doses for the three
NSAIDs (DCF, 60 mg/kg; indomethacin, 10 mg/kg; ketoprofen, 100 mg/kg) were selected
from previously published studies (Fukumoto et al., 2011; Ramirez-Alcantara et al., 2009);
after correction with the interspecies dose scaling factor (× 12 for mouse) (Kirman et al.,
2005), they are comparable to the human therapeutic doses. The intraperitoneal route was
selected to ensure maximal absorption and to minimize drug–drug interactions during
administration; previous data have shown that DCF administered either intraperitoneally or
orally produced a similar extent of enteropathy in rats, due to the critical role of
hepatobiliary excretion of glucuronoconjugates (Seitz & Boelsterli, 1998).
Assessment of small intestinal injury
Mice were euthanized by CO2 inhalation at 18 h after indomethacin, ketoprofen or DCF. A
midline incision was made, and blood was obtained via cardiac puncture. Serum was
prepared and frozen at −80 °C until use for analysis. The entire small intestine (from the
gastroduodenal junction to the ileocecal junction) was removed and opened longitudinally
along the antimesenteric side. The tissue was rinsed in ice-cold phosphate-buffered saline
and incubated for 15 min in 1 mM nitroblue tetrazolium (NBT) solution containing 16 mM
HEPES-NaOH, 125 mM NaCl buffer, 3.5 mM KCl and 10 mM glucose. Next, the tissues
were fixed in 10% zinc formalin for 24 h, washed and transferred to 70% ethanol. The
intestine was metrically divided into four quartiles of equal length and evaluated at 10×
magnification for quantitative and qualitative analysis of mucosal injury, and the lesions
were assigned to the respective quartiles. In addition, the total area of the lesions was
quantified by ImageJ software (NIH). Images were taken using an Olympus SZX16
microscope with an Olympus DP72 camera.
Hepatocyte culture and exposure to chemicals
Hepatocytes were isolated from 25- to 30-g male C57BL/6J mice by collagenase perfusion
through the inferior vena cava, using Percoll purification (Fujimoto et al., 2009). The cells
were resuspended in complete Williams’ medium E containing 10% fetal calf serum, 100 U/
mL penicillin and 100 μg/mL streptomycin. Cell viability was greater than 95% as
determined by trypan blue exclusion. Hepatocytes were plated in 48-well plates (8.0 ×
104cells per well). Plates were coated with 50 μg/mL rat-tail collagen. Hepatocytes were
allowed to attach for 3 h in a humidified atmosphere of 5% CO2, 95% air at 37 °C.
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Subsequently, hepatocytes were washed once and then incubated in the same medium. For
all incubations with chemicals, serum- and antibiotic-free culture medium was used. Release
of lactate dehydrogenase (LDH) into the extracellular medium was taken as an indicator of
cytotoxicity. LDH activity was determined with the CytoTox-One Homogeneous Membrane
Integrity assay (Promega, Madison, WI) and expressed as percentage of activity present in
the medium as compared to the total intra- and extracellular LDH.
Pharmacokinetic profiling of Inhibitor-1
Mice were treated with a single dose (3 mg/kg) of Inh-1 both orally (in 0.5% sodium
carboxymethyl cellulose and 0.1% v/v Tween 80 in water; administered in a volume of 10
ml/kg) or intravenously (in 7.5% N-methyl pyrrolidone and 40% PEG-400 in water;
administered in a volume of 5 ml/kg). 1-Aminobenzotriazole (ABT) was administered by
oral gavage (50 mg/kg in water; 10 ml/kg). Blood samples (approx. 60 μl) were collected
from a set of three mice at pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8 and 24 h (oral) and pre-dose,
0.08, 0.25, 0.5, 1, 2, 4, 8 and 24 h post-dose (intravenous). Immediately after collection of
blood, plasma was prepared and stored at −70 °C until analysis. All samples were processed
for analysis by precipitation using acetonitrile and analyzed by LC-MS-MS (Sai Advantium
Pharma Ltd., Pune, India). In brief, a Merck Chromolith Flash column (4.6 × 25 mm; 5 μm
particle size) was used. The mobile phase consisted of acetonitrile (A) and 0.1% formic acid
(B, gradient mode), with a flow rate of 800–1000 μl/min at 40 °C. Mass spectrometry was
performed with an API 4000 (AB Sciex, Framingham, MA) equipped with a turbo ion spray
source. Validation of the analytical method revealed that the limit of detection was 1.01 ng/
mL, the standard curve accuracy was 84.3–116.4 of the nominal concentration, the slope and
R of the standard curve were 0.00135 and 0.9925, respectively; imipramine was used as
internal standard. The Non-compartmental-Analysis module in WinNonlin (version 5.2;
Pharsight, Mountain View, CA) was used to assess the pharmacokinetic parameters.
Determination of hepatobiliary CDF excretion
Mice were administered Inh-1 or vehicle (0.5% methyl cellulose) by oral gavage b.i.d. (10
μg per mouse) for two days with the last dose given 1 h before anesthesia. Cyclosporin A
was dissolved in 10% (in phosphate-buffered saline) Solutol HS-15 solution and
administered intraperitoneally (50 mg/kg) 1 h before anesthesia as a positive control. Mice
were anesthetized using ketamine (100 mg/kg, ip) and xylazine (10 mg/kg, ip). An incision
was made along the linea alba to expose the gallbladder. The animals were kept at constant
body temperature of 37 °C with the use of a heat lamp. A 4-0 nylon ligature was tied distal
to the gallbladder, which was then punctured with PE10 tubing. The nylon ligature was used
to hold the cannula in place. Mice were then administered 1.5 μmol/mouse of CDFDA in
10% (in saline) DMSO intraperitoneally. Bile was collected in 0.6 ml Eppendorf tubes at 10-
min intervals for 60 min. CDF concentrations in bile (diluted with saline) were determined
by spectrofluorometry (λex/λem, 505/523 nm) in a Tecan multiwell plate reader
(Maennedorf, Switzerland). Standard curves of CDF were prepared daily and were linear
with concentrations.
Statistical analysis
All data were expressed as mean ± SD. If there was normal distribution, a standard analysis
of variance used, followed by Dunnett’s test for multiple comparisons versus the control
group. When normality failed, a Kruskal–Wallis one-way analysis of variance on ranks was
used followed by Dunn’s test for multiple comparison versus the control group. A p value of
< 0.05 was considered significant.
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Jejunal injury induced by indomethacin or ketoprofen is attenuated by Inhibitor-1
pretreatment
We have previously demonstrated that the bacterial β-glucuronidase inhibitor Inh-1 affords
protection against enteropathy induced by DCF (LoGuidice et al., 2012). To ascertain
whether this is a general mechanism for carboxylic acid-containing NSAIDs, as opposed to
an unrelated DCF–specific effect, we assessed the enteric-protective effects of Inh-1 against
indomethacin- or ketoprofen-induced small intestinal injury. Both indomethacin and
ketoprofen are carboxylic acid-containing NSAIDs that are conjugated to glucuronic acid in
the liver, followed by hepatobiliary excretion of the glucuronides and enterohepatic
circulation of the aglycones (Dial et al., 2008; Duggan et al., 1975; Evans, 1992; Julou et al.,
1976). We found that mice which received a single dose of indomethacin alone (10 mg/kg,
ip) developed marked mucosal ulceration at the mesenteric side of the small intestine, with a
typical distribution pattern exhibiting the majority of lesions in quartiles 2 and 3 (Figure
1A–C), whereas vehicle-treated mice were completely devoid of any ulceration (not shown).
In contrast, pretreatment of mice with Inh-1 (10 μg/mouse, po, bid, for 2 days) greatly
decreased the mean number and total area of indomethacin-induced intestinal injury by 90%
and 89%, respectively. In addition, following incubation of the jejunal mucosa with
nitroblue tetrazolium (NBT), large areas of the luminal surface of the indomethacin-treated
mice developed a blue color (indicative of NBT reduction to a blue non-soluble formazan),
while the mucosa of the Inh-1/indomethacin co-treated mice remained unstained. This
suggests that the oxidoreductive stress induced by indomethacin was largely prevented by
Inh-1 pretreatment.
Similarly, administration of ketoprofen alone (100 mg/kg, ip) caused mild jejunal ulceration
in some mice; however, 5/10 mice were non-responders (Figure 1D). Again, Inh-1
significantly attenuated the jejunal lesions induced by ketoprofen; there was only one small
ulcer detected in 1/11 co-treated mice. Taken together, these data indicate that the protection
afforded by the β-glucuronidase inhibitor, Inh-1, is not specific for DCF but that it can be
expanded to other, structurally distinct NSAIDs that are lipophilic, weakly acidic carboxylic
acid-containing molecules subject to hepatic glucuronoconjugation, hepatobiliary excretion
and enterohepatic circulation.
The time window for Inh-1 co-administration with NSAIDs is critical
The putative mode of Inh-1-mediated protection against NSAID enteropathy is inhibition of
bacterial β-glucuronidase in the GI lumen, which implies that the inhibitor be administered
to mice prior to the delivery of glucuronides via bile. Therefore, we next aimed at
determining whether post-treatment with the inhibitor, as opposed to pre-treatment, would
still be effective in alleviating the mucosal injury. The rationale for this was based on the
pharmacokinetic properties of acidic NSAIDs, which undergo enterohepatic cycling, thus
delaying the clearance of the drugs. Mice were treated with a single ulcerogenic dose of
DCF (60 mg/kg, ip), followed by a single dose of Inh-1 or vehicle 3 h post-DCF
administration. The 3-hour time point was chosen because the first cycle of enterohepatic
circulation is completed at this time and the highest rates of biliary output of diclofenac
conjugates have occurred in this time interval (Reuter & Wallace, 1999; Seitz et al., 1998),
while at the same time macroscopically defined ulcers have not yet developed (Ramirez-
Alcantara et al., 2009). We found that post-treatment with Inh-1 reduced the average ulcer
number per mouse by 71% as compared to DCF controls, while the average area of total
ulcers per mouse was not significantly different from that in mice receiving DCF alone
(Figure 2). These data indicate that, although the degree of protection is lower than that in
Inh-1-pretreated mice (LoGuidice et al., 2012), post-treatment with the bacterial β-
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glucuronidase inhibitor still provides partial protection, likely due to the extensive
enterohepatic circulation that is still ongoing at 3 h after a dose of DCF.
Inh-1 does not attenuate acute lethal cell injury in vitro
To address the possibility that Inh-1 may be cytoprotective by inhibiting a pathway
downstream of β-glucuronidase, including a direct inhibitory effect on NSAID-induced cell
death, we exposed cultured primary mouse hepatocytes to DCF in the presence or absence of
Inh-1. As shown in Figure 3, a high cytotoxic concentration of DCF (1000 μM) induced
significant increases in LDH release from the cells, which is consistent with previous reports
(Kretz-Rommel & Boelsterli, 1993; Lim et al., 2006). Inh-1 (100 μM, a non-toxic
concentration that did not significantly increase LDH release as compared to solvent
controls) did not alter the concentration-toxic response curve, indicating that the β-
glucuronidase inhibitor is unlikely to interfere with the cell death-inducing pathways
involved in DCF cytotoxicity. In aqueous solutions containing > 100 μM of Inh-1 (from
stock solutions in DMSO), Inh-1 precipitates as solid material, thus limiting cell-based
studies with higher concentrations.
Pharmacokinetic analysis of Inhibitor-1 in mice
To better characterize the inhibitory potential of the orally administered bacterial β-
glucuronidase inhibitor, we performed a kinetic study to obtain the plasma concentration
over time profile of Inh-1. First, plasma concentrations of Inh-1 were serially determined
following a single oral administration (Figure 4). Maximal plasma levels were attained after
30 min, and the compound was rapidly cleared (Table 1). To determine the absolute
bioavailability (F) of Inh-1, the AUC was compared with that of a single intravenous
administration of Inh-1. We found that F was 21% (Table 1). To ascertain whether this poor
oral bioavailability was caused by poor absorption or by first-pass metabolism, or both, we
pretreated another set of mice with 1-aminobenzotriazole (ABT, 50 mg/kg) (Caldwell et al.,
2005). This non-toxic dose of ABT is sufficient to inhibit a number of CYPs in mice (Balani
et al., 2004). We found that, after oral administration of Inh-1, ABT increased F to 99%,
indicating that Inh-1 is almost fully absorbed in the GI. The data therefore suggest that the
poor absolute bioavailability of Inh-1 was due to CYP-mediated metabolic clearance.
Specifically, we found that ABT also inhibited Inh-1 clearance when the β-glucuronidase
inhibitor was given intravenously rather than orally, strongly suggesting that the CYP-
mediated metabolism of Inh-1 mostly occurred in the liver, not in the gastrointestinal tract.
Effect of Inhibitor-1 on hepatobiliary conjugate excretion
Because Inh-1 was found to be well absorbed and to be metabolized in the liver, we next
conducted a series of experiments to ascertain whether the compound might interfere with
the hepatobiliary excretion of cholephilic compounds, including NSAID glucuronides, and
whether this would be a factor that contributes to the protective effects of the β-
glucuronidase inhibitors. Because glucuronides are primarily exported into bile by the
conjugate export pump, Mrp2 (Abcc2), we used 5 (and 6)-carboxy-2′,7′-dichlorofluorescein
(CDF), a non-metabolizable fluorescent probe that has found wide use as a model substrate
for Mrp2 transport function in vitro and in vivo (Colombo et al., 2012; Zamek-Gliszczynski
et al., 2003). Because hepatic extraction of free CDF from the blood is low in mice, we
administered CDF as its diacetate ester to increase hepatic delivery and to circumvent
hepatic uptake as a rate-limiting factor (Nezasa et al., 2006). CDFDA is avidly taken up by
the liver by diffusion, and rapidly hydrolyzed in the liver. We found that, in the anesthetized
and gall bladder-cannulated mice, CDF-related fluorescence appeared in bile after a lag time
of 10 min, reaching a peak at 30 min and starting to decline afterwards (Figure 5).
Pretreatment with Inh-1 had no significant effect on the excretion rates of CDF. In contrast,
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cyclosporin A (CsA), which was used as a positive control, caused significant reductions in
CDF biliary concentrations. Inh-1 also did not have any significant effect on the total
amount of bile secreted; in vehicle controls, bile flow was stable and ranged from 14 to 18
μl/10 min interval. In contrast, as expected, CsA reduced bile flow by >50% (data not
shown). Collectively, these data suggest that Inh-1 is unlikely to negatively affect
canalicular glucuronide export function in mouse liver.
Discussion
The gut microbiota plays an eminent role in the metabolism and bioactivation of xenobiotics
(Wilson & Nicholson, 2009). The role of one toxicologically relevant intestinal bacterial
enzyme, β-glucuronidase (encoded by the gus gene), has recently been revisited as newly
developed specific bacterial β-glucuronidase inhibitors became available (Wallace et al.,
2010). The data presented in this study are consistent with our hypothesis that oral
administration of one of these bacteria-specific inhibitors of β-glucuronidase (Inh-1) can
greatly attenuate inflammatory ulceration of the small intestine by preventing enzymatic
cleavage of the glucuronides and release of the aglycones in the jejunal lumen. The results
confirm and extend those reported in a previous study (LoGuidice et al., 2012) and include
other acidic and potentially ulcerogenic NSAIDs (indomethacin and ketoprofen). The
conclusion that Inh-1 exerts its effect in the gut lumen and not at a more proximal or more
distal site is supported by the findings that Inh-1 does not interfere with the hepatobiliary
excretion of glucuronides nor directly inhibit the toxic response of target cells exposed to the
aglycone. Furthermore, all three NSAIDs investigated in this study share a number of
common structural and pharmacokinetic features, including a carboxylic acid moiety and the
propensity to undergo glucuronide conjugation, hepatobiliary excretion of the glucuronides,
and enterohepatic circulation of the aglycones. Thus, the major pharmacokinetic determinant
of the GI toxicity of these compounds is the β-glucuronidase-mediated release of the
aglycone(s) that are subsequently taken up by the enterocytes where they initiate a cascade
of events leading to cell injury (Boelsterli et al., 2013).
The quantitative and qualitative profile of NSAID glucuronides other than acyl glucuronides
in bile and the intestinal lumen are currently not known. However, a recent linear ion trap
mass spectrometric analysis has revealed that DCF acyl glucuronide formation may be a
minor route of DCF glucuronidation in mice and that glucuronides formed from the ring-
hydroxylated metabolites may be quantitatively more important (Sarda et al., 2012).
Interestingly, the study also demonstrated that glucuronidation of the 4′-hydroxy and 5-
hydroxy metabolites was directed at the formation of ether rather than acyl conjugates.
Phenolic (ether) glucuronides, similar to the acyl glucuronides, are also excellent substrates
for bacterial β-glucuronidase (Wallace et al., 2010). Whether and how these oxidative
metabolites of DCF are taken up by enterocytes is not clear; however, it has been
demonstrated that intestinal CYP-mediated metabolism is critical for enteropathy to develop,
because intestine-specific genetic elimination of CYP reductase resulted not only in a great
decrease of intestinal DCF oxidative metabolite formation, but also in full protection against
DCF-induced enteropathy (Zhu & Zhang, 2012).
Pharmacologic inhibition of NSAID-induced enteropathy can be aimed at different
molecular targets. For example, indomethacin enteropathy has recently been reported to be
attenuated by co-administration of hemin, a heme oxygenase-1 inducer (Yoriki et al., 2012).
Hemin clearly interferes with the second hit during the pathogenesis of NSAID-induced
small intestinal injury, i.e. the mucosal inflammatory response. Here, we demonstrate that
inhibition of the release of the parent indomethacin (or an oxidative metabolite) from the
glucuronide conjugate, which causes the first hit, is also a highly effective mechanism to
protect the jejunal mucosa. However, for indomethacin, the biliary metabolite profile is less
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well known as compared to that of DCF. Apart from CYPs, other enzymes could play a key
role in the bio-activation of the compound. For example, a major indomethacin metabolite,
desmethyldeschlorobenzoyl indomethacin, has been shown to be activated in vitro by
neutrophils via myeloperoxidase-catalyzed oxidation to a reactive intermediate, possibly an
iminoquinone (Ju & Uetrecht, 1998). To what extent this route would play a role in
indomethacin enteropathy is currently not known.
With a view to potential clinical applications of such small molecule inhibitors of bacteria-
specific β-glucuronidase against NSAID-associated small intestinal injury, a number of
points have to be considered. First, because the mode of action of the inhibitor is based on
an early event (prior to intestinal absorption of the NSAIDs), such a mechanism would
imply that the β-glucuronidase inhibitor would find a potential role as a prophylactic, rather
than a therapeutic, agent. Although our data demonstrate that, if given 3 h post-DCF, the
protective effects of Inh-1 is still partially retained, the inhibitor needs to be administered
prior to the induction of jejunal ulceration. Second, ideally such an inhibitor should be either
minimally absorbed and stay in the intestinal lumen, where it can react with the luminal
bacterial enzyme, or it should be rapidly eliminated in order not to interfere with
endogenous glucuronide homeostasis. For Inh-1, we show that even in view of its short
systemic half-life (<1 h) and rapid hepatic clearance, the inhibitor prevents the progression
of the disease in the mouse model. Finally, it must be assessed to what extent the mouse
model reflects the human situation with respect to the extent of enterohepatic circulation;
unfortunately quantitative comparable data are currently not available.
Conclusions
Inhibitor-1 (Inh-1), a selective small-molecule inhibitor of bacteria-specific β-glucuronidase,
protects against small intestinal injury induced by the carboxylic acid-containing NSAIDs
diclofenac, indomethacin or ketoprofen by preventing the hydrolytic cleavage of the acyl
glucuronides and/or phenol glucuronides that are excreted into bile. These results are
presently limited to the mouse model, and the translation of these observations to humans
remains uncertain. However, bacterial β-glucuronidase could be explored as a new
pharmacologic target in the development of GI-protective drugs against NSAID-induced
enteropathy.
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Protective effects of Inhibitor-1 (Inh-1) on indomethacin (IND)-induced ulceration. Mice
received a single dose of IND (10 mg/kg, ip) with or without pretreatment with Inh-1 (10
μg/mouse, bid, ×2 days, last dose was given 1 h prior to IND). Ulcer numbers (A) and area
(B) were determined in the four quartiles (Q1–Q4) of the small intestine 18 h post-dose. Q1
did not exhibit any ulceration. Data are mean ± SD (n = 5 mice per group. *, p<0.05 versus
IND alone. (C) Micrograph of jejunal mucosa (luminal side) 18 h after IND treatment with
or without Inh-1. Arrow, typical ulcer. The dark color of the nitroblue tetrazolium (NBT)-
stained intestinal tissue in the IND-treated mice is due to oxidoreductive stress converting
the soluble NBT to the insoluble formazan. (D) Protective effect of Inh-1 on ketoprofen
(KPR)-induced enteropathy. Mice received a single oral dose of KPR (100 mg/kg, ip) or
vehicle, with or without pretreatment with Inh-1 (10 μg/mouse, bid, ×2 days, last dose was
given 1 h prior to KPR). Total ulcer numbers were determined 18 h post-dose. Data are
mean ± SD (n = 10–11 mice per group). *, p<0.05 versus KPR alone.
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Effects of post-treatment with Inh-1 on diclofenac (DCF)-induced small intestinal injury.
Mice were given a single oral dose of Inh-1 (10 μg/mouse) or vehicle (0.5% methyl
cellulose) 3 h after a single intraperitoneal dose of DCF (60 mg/kg). The mice were
euthanized 18 h after DCF, and the small intestinal mucosa processed for quantitative
analysis of ulcer numbers (A) and total ulcer area per mouse, as determined by morphometry
(B) across quartiles 1–4. Data are mean ± SD (n = 5–6 mice per group). *, p<0.05 versus
DCF alone.
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Effects of Inh-1 on diclofenac (DCF)-induced acute cell injury in cultured mouse
hepatocytes. Overnight-precultured primary mouse hepatocytes were incubated with DCF
(500 or 1000 μM) in the presence or absence of Inh-1 (100 μM), and LDH activity in the
culture media was assessed after 24 h exposure (100% = both intra- and extracellular LDH
activity). Data are mean ± SD of triplicate wells using two independent cell preparations.
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Mean plasma concentration-time profiles of Inh-1 following a single oral dose (A) or a
single intravenous dose (B). Inhibitor-1 was administered at a dose of 3 mg/kg to mice with
or without pretreatment with 1-aminobenzotriazole (ABT, 50 mg/kg, po) which was given 2
h prior to Inh-1. Filled symbols, ABT; white symbols, vehicle. Data points are mean of three
mice.
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Effect of Inhibitor-1 on the hepatobiliary excretion rate of the Mrp2 substrate, 5 (and 6)-
carboxy-2′,7′-dichlorofluorescein (CDF). Mice were pretreated with Inh-1 or vehicle as
described in the section “Materials and methods”. Following anesthesia, the gall bladder was
cannulated, and bile flow was monitored until it was stable. The mice received a single
injection of CDF diacetate (1.5 μmol/mouse), and bile was collected at 10-min intervals.
CDF concentrations were determined by fluorescence spectrophotometry; bile flow was
determined gravimetrically (assuming a specific mass of bile of 1.0). Data are mean ± SD (n
= 5 mice per group). *, p<0.05 versus vehicle control.
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